(SNY) Sanofi - Ratings and Ratios
Vaccines, Oncology, Immunology, Neurology, Rare Diseases
SNY EPS (Earnings per Share)
SNY Revenue
Description: SNY Sanofi
Sanofi (NASDAQ:SNY) is a global biopharma company that discovers, develops, manufactures, and markets therapeutic products across several therapeutic areas, including immunology & inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel/endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.
The firm maintains an extensive partnership network to augment its pipeline: a collaboration with Exscientia to co-develop up to 15 novel small-molecule candidates for oncology and immunology; agreements with ABL Bio (ABL301 for α-synucleinopathies), Innate Pharma (NK-cell engager targeting B7-H3), Blackstone Life Sciences (clinical development support), IGM Biosciences (IgM antibody platform), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and a co-promotion deal with Provention Bio for teplizumab. Sanofi also partners with Abu Dhabi’s Department of Health on global vaccine initiatives.
Key recent metrics (FY 2023) show revenue of €42.1 billion, with vaccines contributing roughly 15 % and a 9 % YoY increase in oncology sales driven by its Libtayo franchise. R&D expenditure remained steady at €6.5 billion (≈15 % of sales), reflecting continued investment in protein-degrader and gene-editing platforms. Sector-wide drivers that materially affect Sanofi’s outlook include an aging global population (projected to increase demand for chronic-disease therapeutics by ~3 % CAGR through 2030) and heightened vaccine spending post-COVID-19, which is expected to lift the overall vaccine market size to > $70 billion by 2028.
For a deeper quantitative assessment of SNY’s valuation and scenario-based risk/reward profile, the ValueRay platform provides a curated set of peer-adjusted multiples and forward-looking financial models.
SNY Stock Overview
| Market Cap in USD | 124,046m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2002-07-01 |
SNY Stock Ratings
| Growth Rating | 35.8% |
| Fundamental | 55.5% |
| Dividend Rating | 55.8% |
| Return 12m vs S&P 500 | -18.4% |
| Analyst Rating | 4.18 of 5 |
SNY Dividends
| Dividend Yield 12m | 4.49% |
| Yield on Cost 5y | 5.37% |
| Annual Growth 5y | 3.83% |
| Payout Consistency | 97.2% |
| Payout Ratio | 53.3% |
SNY Growth Ratios
| Growth Correlation 3m | -15.9% |
| Growth Correlation 12m | -8.6% |
| Growth Correlation 5y | 70.9% |
| CAGR 5y | 11.72% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.54 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.45 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | -15.72 |
| Beta | 0.442 |
| Volatility | 23.97% |
| Current Volume | 2074.3k |
| Average Volume 20d | 3020.2k |
| Stop Loss | 47.7 (-3.1%) |
| Signal | 0.77 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (9.13b TTM) > 0 and > 6% of Revenue (6% = 2.59b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.45% (prev 0.13%; Δ 18.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 3.56b <= Net Income 9.13b (YES >=105%, WARN >=100%) |
| Net Debt (6.93b) to EBITDA (9.47b) ratio: 0.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.47b) change vs 12m ago -1.36% (target <= -2.0% for YES) |
| Gross Margin 71.63% (prev 52.17%; Δ 19.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.86% (prev 30.41%; Δ 3.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.12 (EBITDA TTM 9.47b / Interest Expense TTM 877.8m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 55.48
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 1.88% = 0.94 |
| 3. FCF Margin 4.95% = 1.24 |
| 4. Debt/Equity 0.32 = 2.45 |
| 5. Debt/Ebitda 0.73 = 2.10 |
| 6. ROIC - WACC (= 0.93)% = 1.16 |
| 7. RoE 12.39% = 1.03 |
| 8. Rev. Trend -27.16% = -2.04 |
| 9. EPS Trend -27.94% = -1.40 |
What is the price of SNY shares?
Over the past week, the price has changed by +0.05%, over one month by +5.58%, over three months by +1.38% and over the past year by -6.41%.
Is Sanofi a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNY is around 50.03 USD . This means that SNY is currently overvalued and has a potential downside of 1.65%.
Is SNY a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.5 | 24.9% |
| Analysts Target Price | 61.5 | 24.9% |
| ValueRay Target Price | 54.7 | 11.2% |
Last update: 2025-10-06 02:02
SNY Fundamental Data Overview
P/E Trailing = 16.8543
P/E Forward = 9.9701
P/S = 2.7121
P/B = 1.4874
P/EG = 0.773
Beta = 0.442
Revenue TTM = 43.13b EUR
EBIT TTM = 8.00b EUR
EBITDA TTM = 9.47b EUR
Long Term Debt = 13.20b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.56b EUR (from shortTermDebt, last quarter)
Debt = 22.29b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.93b EUR (from netDebt column, last quarter)
Enterprise Value = 113.61b EUR (106.68b + Debt 22.29b - CCE 15.36b)
Interest Coverage Ratio = 9.12 (Ebit TTM 8.00b / Interest Expense TTM 877.8m)
FCF Yield = 1.88% (FCF TTM 2.13b / Enterprise Value 113.61b)
FCF Margin = 4.95% (FCF TTM 2.13b / Revenue TTM 43.13b)
Net Margin = 21.16% (Net Income TTM 9.13b / Revenue TTM 43.13b)
Gross Margin = 71.63% ((Revenue TTM 43.13b - Cost of Revenue TTM 12.24b) / Revenue TTM)
Gross Margin QoQ = 72.13% (prev 72.76%)
Tobins Q-Ratio = 0.91 (Enterprise Value 113.61b / Total Assets 124.96b)
Interest Expense / Debt = 0.39% (Interest Expense 87.0m / Debt 22.29b)
Taxrate = 15.68% (230.0m / 1.47b)
NOPAT = 6.75b (EBIT 8.00b * (1 - 15.68%))
Current Ratio = 1.27 (Total Current Assets 37.02b / Total Current Liabilities 29.06b)
Debt / Equity = 0.32 (Debt 22.29b / totalStockholderEquity, last quarter 70.01b)
Debt / EBITDA = 0.73 (Net Debt 6.93b / EBITDA 9.47b)
Debt / FCF = 3.24 (Net Debt 6.93b / FCF TTM 2.13b)
Total Stockholder Equity = 73.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.30% (Net Income 9.13b / Total Assets 124.96b)
RoE = 12.39% (Net Income TTM 9.13b / Total Stockholder Equity 73.65b)
RoCE = 9.22% (EBIT 8.00b / Capital Employed (Equity 73.65b + L.T.Debt 13.20b))
RoIC = 7.30% (NOPAT 6.75b / Invested Capital 92.41b)
WACC = 6.38% (E(106.68b)/V(128.96b) * Re(7.64%) + D(22.29b)/V(128.96b) * Rd(0.39%) * (1-Tc(0.16)))
Discount Rate = 7.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈2.95b ; Y1≈1.94b ; Y5≈885.5m
Fair Price DCF = 7.14 (DCF Value 17.41b / Shares Outstanding 2.44b; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -27.94 | EPS CAGR: -15.37% | SUE: -0.24 | # QB: 0
Revenue Correlation: -27.16 | Revenue CAGR: -7.08% | SUE: 0.58 | # QB: 0
Additional Sources for SNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle